Quest Diagnostics Back to School program
Helping you and your students get back to campus
Quest Diagnostics understands that the COVID-19 pandemic has had a significant impact on higher education, and that distance learning doesn’t replace the value of campus life. That’s why we have created the Back to School program—a solution to help your students, faculty, and staff understand their risk so that they can stay focused on education.
The program combines prescreening with SARS-CoV-2 (COVID-19) antibody testing for an asymptomatic person and molecular testing for a symptomatic or high-risk person to provide insights into their COVID-19 status. We can customize the program meet your unique needs and provide additional support for continued testing throughout the school year.
Fill out the form below to be contacted by one of our representatives and learn how we can work together to get your students back to school.
* Required fields.
This list is intended for adults at least 18 years of age in the USA.
The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARSCoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.
· The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
· All tests have been authorized by FDA under EUAs for use by authorized laboratories;
· The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
· The molecular tests have been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens; and,
· All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.